MedTrace Logo

BElumosudil for Bronchiolitis Obliterans Prevention/Therapy (BEBOP)

NCT05922761 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 45

Last updated 2026-02-11

No results posted yet for this study

Summary

The goal of this research study is to test the efficacy of a novel immunosuppressive agent, belumosudil, in allogeneic hematopoietic stem cell transplant (HSCT) recipients who have been newly diagnosed or have developing (early stage) bronchiolitis obliterans syndrome (BOS).

The name of the study drugs involved in this study are:

* Belumosudil (an immunotherapy)
* Fluticasone (an intranasal corticosteroid)
* Azithromycin (an antibiotic)
* Montelukast (a leukotriene receptor antagonist)
* Prednisone (a corticosteroid)

Conditions

Interventions

DRUG

Belumosudil

Kinase inhibitor, tablet taken orally

DRUG

Fluticasone

Via inhalation by metered-dose inhaler.

DRUG

Azithromycin

Semi-synthetic macrolide antibiotic, taken orally

DRUG

Prednisone

Corticosteroid, taken orally

DRUG

Montelukast

Leukotriene Receptor Antagonist, taken orally

Sponsors & Collaborators

Principal Investigators

  • Corey Cutler, MD, MPH · Dana-Farber Cancer Institute

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-05-31
Primary Completion
2027-06-30
Completion
2027-12-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05922761 on ClinicalTrials.gov